Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells

Yanling Wang,1 Haineng Xu,1 Tianrun Liu,1 Menggui Huang,1 Param-Puneet Butter,1 Chunsheng Li,2 Lin Zhang,2 Gary D. Kao,1 Yangqing Gong,3 Amit Maity,1 Constantinos Koumenis,1 and Yi Fan1,4
1Department of Radiation Oncology, 2Department of Obstetrics & Gynecology, 3Division of Human Genetics and Translational Medicine, Department of Medicine, and 4Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Introduction
Cancer stem cells (CSCs) — known to be resistant to genotoxic radiation and chemotherapy — are fundamental to therapy failure and cancer relapse. Here, we reveal that glioma CSCs are hypersensitive to radiation, but a temporal DNA repair mechanism converts the intrinsic sensitivity to genomic instability and treatment resistance. Transcriptome analysis identifies DNA-dependent protein kinase (DNA-PK) as a predominant DNA repair enzyme in CSCs. Notably, DNA-PK activity is suppressed after irradiation when ROS induce the dissociation of DNA-PKcs with Ku70/80, resulting in delayed DNA repair and radiosensitivity; subsequently, after ROS clearance, the accumulated DNA damage and robust activation of DNA-PK induce genomic instability, facilitated by Rad50-mediated cell-cycle arrest, leading to enhanced malignancy, CSC overgrowth, and radioresistance. Finally, we show a requisite in vivo role for DNA-PK in CSC-mediated radioresistance and glioma progression. These findings identify a time-sensitive mechanism controlling CSC resistance to DNA-damaging treatments and suggest DNA-PK/Rad50 as promising targets for CSC eradication.
Results

Time-dependent radioresistance is associated with delayed H2AX phosphorylation and DNA repair after radiation in CSCs. We investigated the responses of patient GBM tumor-derived CSCs to radiation and compared them to those of matched non–cancer stem cells (non-CSCs). CSCs and non-CSCs were cultured in same serum-free stem cell medium for analyses. Unexpectedly, during the first 1 week after irradiation, cell proliferation analyses showed that multiple lines of CSCs were consistently hypersensitive to radiation when compared with non-CSCs (differentiated, induced by serum) and glioma cell lines. Remarkably, despite being hypersensitive to radiation initially, the CSCs eventually regrew in the later phase, while the numbers of viable control cells were continuously reduced (Figure 1A and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.98096DS1), suggesting that a temporal mechanism may contribute to CSC radioresistance. These findings suggest that a time-sensitive mechanism may contribute to CSC radioresistance.

In addition to the initial hypersensitivity to radiation and subsequent radioresistance in CSCs, DNA comet assays revealed a distinct pattern of DNA damage in CSCs following irradiation. Specifically, in contrast to the peak in DNA damage at 4 hours after irradiation in non-CSCs (similar dynamics have been extensively documented in a variety of somatic cell types), a continuously increasing DNA damage during 48 hours after radiation (Figure 1B), followed by a gradual decrease to the basal level in next 2–3 days (data not shown), was observed in CSCs. Moreover, irradiated CSCs showed a substantial delay in H2AX phosphorylation at Ser\(^{159}\) (γ-H2AX), a hallmark feature of DNA damage and repair (Figure 1C). CSCs, non-CSCs, and U87 glioma cells or primary GBM cells (data not shown) had different patterns of γ-H2AX that peaked at 72, 12, and 0.5 hours after irradiation, respectively. Similar results were observed in differentiated or undifferentiated multiple CSC lines derived from different patients (Supplemental Figure 2) and in CD133\(^{+}\) and CD133\(^{-}\) cells in same patient (Figure 1D). Considering the major role of nonhomologous end joining (NHEJ) over that of homologous recombination for repairing double-stranded DNA breaks in multicellular eukaryotes, such as humans and mice (16), we analyzed NHEJ activity in irradiated CSCs. Consistent with the observation in γ-H2AX dynamics, DNA NHEJ analysis revealed robust, delayed DNA repair at 48 hours after irradiation in CSCs (Figure 1E). Together, these findings suggest CSCs develop elongated DNA damage and delayed DNA repair after radiation, which may induce radiosensitivity during the initial phase.

DNA-PK is selectively required for H2AX phosphorylation after irradiation and DNA repair in CSCs. To explore potential molecular mechanisms underlying the temporal process of DNA damage and repair in CSCs, we utilized deep RNA sequencing (RNA-seq) to analyze the expression of DNA damage and repair-associated genes at the transcriptome level. Our gene set analysis of CSCs and matched non-CSCs revealed a stemness-associated upward trend of global gene expression, particularly in NHEJ, mismatch excision repair, and homologous recombination pathways (Figure 2A and Supplemental Figure 3). Consistent with the stronger NHEJ activities in CSCs before and after irradiation (Figure 1E), transcription of DNA-PK catalytic subunit (DNA-PKcs, PRKDC), a key enzyme that regulates NHEJ, was increased by 80% in CSCs (Figure 2A). Moreover, DNA-PKcs phosphorylation at Ser\(^{2056}\), a measure of its activation, was delayed after irradiation in CSCs and peaked at 48 hours (Figure 2B), which is consistent with the delayed DNA repair kinetics (Figure 1C). In contrast, the phosphorylation of ATM and ATR, two other key DNA repair enzymes, occurred rapidly after radiation (Figure 2B). These findings provide evidence that DNA-PKcs may play a selective role in regulating DNA repair in CSCs. Consistently, pharmacological inhibition of DNA-PK selectively and almost completely abolished radiation-induced γ-H2AX in CSCs but not in non-CSCs (Figure 2C). Likewise, knockdown of DNA-PKcs, but not ATM or ATR, remarkably abrogated radiation-induced γ-H2AX and DNA repair during the later phase (Figure 2, D and E) and induced more DNA damage (Figure 2F).

DNA-PKcs is preferentially expressed in CSCs and is required for CSC survival after radiation. To understand the selective role of DNA-PKcs in DNA repair in CSCs, we examined the expression levels of key DNA repair enzymes, including DNA-PK, ATM, and ATR. RNA-seq revealed robust increases in DNA-PKcs in CSCs (Figure 3A). Immunoblot analysis verified stemness-associated DNA-PKcs expression in CSCs (Figure 3B). Importantly, CSCs showed robust, intrinsic DNA-PKcs expression, as indicated by 8-fold higher fragments per kilobase of transcript per million mapped reads (FPKM) values than ATM (Supplemental Figure 4A). Analysis of The Cancer Genome Atlas (TCGA) database showed a 3-fold increase in DNA-PK expression relative to ATM in GBM tumor cells (Supplemental Figure 4B), suggesting that DNA-PKcs may serve as a key regulatory enzyme for DNA repair in CSCs. Consistent with its preferential expression in...
CSCs, knockdown of DNA-PKcs, or, to a lesser extent, ATM, markedly sensitized radiation-induced cytotoxicity in multiple lines of CSCs (Figure 3C and Supplemental Figure 5) but not in non-CSCs (Figure 3D).

**ROS induces temporal DNA-PKcs inhibition by disrupting Ku70/80 binding to DNA-PKcs, leading to delayed H2AX phosphorylation and DNA repair.** We further explored the regulatory mechanisms for DNA-PKcs–mediated DNA repair in CSCs. Consistent with previous reports showing the robust ability of CSCs to scavenge ROS (17), our data showed more rapid clearance of peroxide hydrogen (H2O2) and total ROS in CSCs than in non-CSCs (Figure 4A and Supplemental Figure 6). Interestingly, ROS concentration reached the basal level 24 hours after irradiation, which coincided with DNA-PK activation. To test whether ROS regulates

---

**Figure 1.** Time-dependent radioresistance is associated with increased DNA damage and delayed γ-H2AX and DNA repair after irradiation in glioma CSCs. (A) Human patient-derived IN528 CSCs and the matched non–cancer stem cells (non-CSCs) were cultured in serum-free stem cell medium and either irradiated by 5-Gy x-ray or were not irradiated. The number of viable cells was determined using cell viability assays. The data are presented as a percentage based on the number of viable nonirradiated cells of the same type (mean ± SEM, n = 3). (B) IN528 CSCs and matched non-CSCs were irradiated with 5-Gy x-ray. Cells were harvested at different times after irradiation. DNA damage was assessed using the single-cell gel electrophoresis comet assay with a neutral condition. Representative images and quantification of the percentage of DNA in the comet tails (mean ± SD). Scale bar: 50 μm. (C) IN528 CSCs and matched non-CSCs and glioma U87 cells were irradiated with 5-Gy x-ray. Cell lysates were immunoblotted with anti–P-H2AX-Ser139 (γ-H2AX) and anti-GAPDH antibodies. Representative blots. γ-H2AX band intensity was quantified and expressed as a percentage of its expression level before radiation. (D) CD133+ CSCs and CD133− non-CSCs were isolated from IN528 GBM cells and irradiated with 5-Gy x-ray. Cell lysates were immunoblotted with anti–P-H2AX-Ser139 (γ-H2AX) and anti-GAPDH antibodies. (E) IN528 CSCs and matched non-CSCs were irradiated with 5-Gy x-ray. Nuclear extracts were incubated with linearized DNA in NHEJ reaction buffer, followed by electrophoresis and gel imaging. The reaction mixtures were immunoblotted using an anti-PCNA antibody. Band intensity of multimers was analyzed.
DNA-PKcs activity, CSCs were pretreated with the ROS scavenger TEMPOL, followed by x-ray irradiation. Our data showed that scavenging ROS with TEMPOL remarkably altered DNA-PKcs phosphorylation, shifting the peak phosphorylation from 48 hours to 6 hours and diminishing DNA-PKcs activation after 12 hours following irradiation, although it did not affect ATM phosphorylation (Figure 4B).

Figure 2. DNA-PK is selectively required for after radiation γ-H2AX and DNA repair in CSCs. (A) RNA was isolated from IN528, T3961, and T4121 CSCs and from their corresponding matched non-CSCs and subjected to deep RNA-sequencing analysis. Approximately 200 genes encoding all known human proteins associated with DNA damage and repair were classified. Generated gene sets were ranked based on their mean percentage expression changes in CSCs versus non-CSCs and plotted as mean ± SEM. Genes with expression changes of more than 50% are annotated. (B) IN528 CSCs were irradiated with 5-Gy x-ray. Cell lysates were harvested at different time points after irradiation and subjected to immunoblot analysis. (C) IN528 CSCs and matched non-CSC cells were pretreated with 1 μM NU7441 (DNA-PK inhibitor), KU60019 (ATM inhibitor), or VE821 (ATR inhibitor) and irradiated by 5-Gy x-ray. At 48 hours after irradiation, cell lysates were collected and immunoblotted with anti–P-H2AX-Ser139 and anti-GAPDH antibodies. (D–F) IN528 CSCs were transduced with lentivirus to express shRNAs targeting control GFP, DNA-PK, ATM, or ATR, followed by puromycin selection for stable expression cell lines. Cells were irradiated with 5-Gy x-ray. (D) Cells were harvested at 48 hours after irradiation. Cell lysates were subjected to immunoblot analysis. (E) Cells were harvested 48 hours after irradiation. Nuclear extracts were incubated with linearized DNA in NHEJ reaction buffer, followed by electrophoresis and gel imaging. The reaction mixtures were immunoblotted with anti-PCNA antibody. (F) Cells were harvested at different time points after irradiation. DNA damage was assessed using a single-cell gel electrophoresis comet assay. Quantification of the percentage of DNA in the comet tails is shown (mean ± SD).
TEMPOL pretreatment substantially restored the interaction between DNA-PKcs and Ku70/80, which is known to induce DNA-PK autophosphorylation and activation, before and, to a greater extent, after radiation (Figure 4C), suggesting that ROS regulates DNA-PKcs binding to Ku70/80, leading to the inhibition of its activity. Furthermore, ROS scavenging remarkably accelerated the appearance of γ-H2AX (Figure 4D) and abrogated the DNA repair at 48 hours after irradiation (Figure 4E), most likely due to suppressed DNA-PK activity at that time (Figure 4B).

Delayed DNA-PK activation induces genomic instability and enhances cell malignancy in CSCs. Accumulation of DNA damage is known to induce genomic instability, leading to cell transformation and tumorigenesis. Therefore, we hypothesized that delayed DNA-PK activation and DNA repair may induce genomic instability in CSCs, driving cell regrowth and radioresistance. To test our hypothesis, we determined the effects of radiation on genomic stability in CSCs and non-CSCs. Our data showed that radiation induced the formation of a micronucleus, a marker of genomic instability, in CSCs, whereas an approximately 40% decrease in micronucleus formation was observed in irradiated non-CSC cells (Figure 5A). Furthermore, flow cytometric analysis showed that radiation induced a gradual increase in chromosomal aneuploidy in CSCs; in contrast, radiation induced half as much aneuploidy in non-CSC cells (Figure 5, B and C), suggesting a critical role for stemness in radiation-induced genomic instability.

To test the role of DNA-PK in radiation-induced chromosomal instability, CSCs were pretreated with specific pharmacological inhibitors of DNA-PK or ATM, followed by radiation. Our data showed that inhibition of DNA-PK, but not ATM, markedly inhibited radiation-induced aneuploidy in CSCs (Figure 5D) and neither inhibition substantially affected radiation-induced aneuploidy in non-CSCs (Supplemental Figure 7). In addition, we also tested the role of Rad50 in cell cycle and aneuploidy regulation, which was identified as an overexpressed DNA repair-associated gene by our RNA-seq analysis (Figure 2A). Our data showed that shRNA-mediated knockdown of Rad50, but not DNA-PK, inhibited radiation-induced G2/M arrest of cell cycle in CSCs (Figure 5, E and F). Moreover, knockdown of DNA-PK or Rad50, but not ATM, inhibited radiation-induced aneuploidy in CSCs (Figure 5G), implicating that Rad50 may facilitate the delayed DNA-PK activation-mediated genomic instability by regulating G2 cell cycle arrest. Furthermore, DNA-PKcs knockdown, and, to a lesser extent, Rad50 knockdown, abolished the CSC regrowth 7 days after irradiation (Figure 5H) and abrogated cell survival after irradiation (Figure 5I). Together, these findings suggest that DNA-PK–mediated temporal regulation of DNA repair is critical for radiation-induced genomic instability in CSCs.
DNA-PK is critical for genomic instability and radioresistance in CSCs in vivo. To rigorously determine the role of DNA-PK in maintaining genomic instability and CSC radioresistance in vivo, we induced orthotopic gliomas in a xenograft nude mouse model by using human CSCs, followed by CT-guided stereotactic radiotherapy (Figure 6A). Our data showed that low-dose (3-Gy) radiation did not significantly improve animal survival in control mice (Figure 6B). However, either DNA-PKcs or ATM knockdown sensitized CSC-derived gliomas to radiation, leading to increased mouse survival. Notably, around 30% of the irradiated mice with DNA-PKcs–knockdown tumors survived after all of the other mouse groups had died (at day 70), and 10% of these mice survived for at least 90 days, when the experiment was terminated (Figure 6B). Consistent with the critical role of DNA-PKcs in mouse survival, knockdown of DNA-PKcs, but not ATM, plus radiation significantly reduced tumor growth, as indicated by a 65% decrease in average tumor volume (at day 41 after tumor implantation) (Figure 6C). Furthermore, DNA-PK knockdown robustly enhanced radiation-induced tumor necrosis and increased cell apoptosis, as shown by TUNEL staining (Figure 6, D and E). Importantly, knockdown of DNA-PKcs, but not ATM, efficiently abrogated radiation-induced genomic instability, as indicated by a marked reduction in aneuploid cell populations in the tumors (Figure 6F). Together, these data indicate that DNA-PK plays a critical role in radioresistance and radiation-induced genomic instability in CSCs in vivo.

Pharmacological inhibition of DNA-PK in GBM-bearing mice overcomes CSC-mediated radioresistance and leads to enhanced survival. Finally, we tested an experimental therapy for CSC eradication by utilizing a genetic GBM mouse model that recapitulates major pathological features of human GBM (Figure 7A). Fractioned...
Figure 5. Delayed DNA-PK activation induces genomic instability and enhances cell malignancy in CSCs. (A–C) INS528 CSCs and matched non-CSCs were either irradiated with 5-Gy x-ray or were not irradiated (sham control). (A) At 2 days after irradiation, the cells were subjected to micronucleus analyses. Representative images and quantification of data (mean ± SD, n = around 1,000 cells). Scale bar: 50 μm. (B and C) Cells were analyzed by flow cytometry for aneuploidy. (B) Representative sorting. (C) Quantified data (mean ± SEM, n = 3). (D) INS528 CSCs were pretreated with 1 μM KU60019 (inhibitor of ATM [iATM]), NU7441 (inhibitor of DNA-PK [iDNA-PK]), or control 0.1% DMSO, and irradiated with 5-Gy x-ray. At different times after irradiation, cells were subjected to aneuploidy analysis by flow cytometry (mean ± SEM, n = 3). (E–I) INS528 CSCs were transduced with lentivirus that expresses shRNAs targeting control GFP, DNA-PK, Rad50, or ATM, followed by puromycin selection for stable expression cell lines. Cells were irradiated by 5-Gy x-ray. (E) Cells were analyzed by immunoblot. (F) 24 hours after irradiation, cells were stained with propidium iodide and analyzed by flow cytometry for cell cycle. Representative sorting and quantitative results (mean ± SEM, n = 3). (G) At 72 hours after irradiation, cells were stained with propidium iodide and analyzed by flow cytometry for cell aneuploidy (mean ± SEM, n = 3). (H) Cells were subjected to viability analysis at different time points after radiation (mean ± SEM, n = 3–6). (I) At 2 weeks after irradiation, cells were subjected to neurosphere formation/survival fraction analysis (mean ± SEM, n = 3–5).
high-dose (10-Gy) radiation significantly improved mouse survival by 9 days, whereas pharmacological inhibition of ATM or DNA-PK alone did not increase survival (Figure 7B). Importantly, DNA-PK inhibition induced significant sensitization to radiotherapy, resulting in a nearly doubled overall animal survival (from 22 days to 41.5 days). In contrast, ATM inhibition moderately improved the radiotherapy (from 22 days to 34 days). Moreover, radiotherapy plus inhibition of DNA-PK, but not inhibition of ATM, significantly reduced tumor growth, as indicated by a 70% decrease in average tumor volume (at day 24 after tumor implantation) (Figure 7C). Furthermore, radiotherapy plus DNA-PK inhibition, but not ATM inhibition, efficiently eradicated the CD133+ CSC population (Figure 7, D and E). In addition, radiotherapy plus DNA-PK inhibition suppressed tumor progression and abrogated hemorrhagic necrosis, a defining pathological feature of GBM (Figure 7F), likely due to the eradication of CSCs. Together, these results provide evidence that radiotherapy plus DNA-PK inhibition may be an efficient approach for eradicating CSCs in gliomas.

Collectively, these findings reveal a time-dependent DNA repair mechanism that drives treatment resistance in CSCs (Figure 8). Specifically, DNA-PKcs activity is suppressed after irradiation by ROS-induced dissociation of Ku70/80, leading to delayed DNA repair and radiosensitivity. Subsequently, following ROS clearance, the accumulated DNA damage accumulation and the robust reactivation of DNA-PK induce genomic instability, resulting in cell malignancy and eventually leading to CSC overgrowth and radiore- clearance, the accumulated DNA damage accumulation and the robust reactivation of DNA-PK induce genomic instability, resulting in cell malignancy and eventually leading to CSC overgrowth and radiore- clearance, the accumulated DNA damage accumulation and the robust reactivation of DNA-PK induce genomic instability, resulting in cell malignancy and eventually leading to CSC overgrowth and radioresistance. In addition, Rad50 promotes cell cycle G2 arrest, facilitating the DNA-PK–mediated processes.

Discussion
It is increasingly recognized that CSCs are a major driver of treatment resistance and cancer recurrence and metastasis. Multiple mechanisms contribute to the resistance of CSCs to treatment, including cell dormancy, increased drug efflux and detoxification, activation of antiapoptotic signal pathways, robust abilities to scavenge ROS, and enhanced activities for DNA repair (17, 18). Notably, previous studies suggest that high intrinsic DNA repair activity — mediated by Chk1/2 — drives radioresistance in glioma CSCs (9). Our RNA-seq–based findings, which show that CSCs exhibit a global increase in the expression of most DNA repair-associated genes, seem to support this prevailing theory. However, we also discovered that glioma CSCs are hypersensitive to radiotherapy during the initial phase (as evidenced by more DNA damage and less cell viability after irradiation), which is consistent with more recent studies showing radiosensitivity in multiple lines of patient-derived glioma CSCs (12), suggesting that treatment resistance may be time dependent in different CSCs. More importantly, our study reveals a DNA-PK–mediated mechanism that temporally regulates DNA repair and leads to treatment resistance by inducing genomic instability in CSCs (Figure 8), suggesting that radiosensitivity in CSCs is not simply driven by intrinsically enhanced DNA repair.

H2AX phosphorylation at Ser139 (γ-H2AX) is a hallmark feature of DNA damage and repair (19, 20). Rapid induction of γ-H2AX, which peaks at 0.5–2.0 hours after irradiation, has been extensively document- ed in a variety of somatic cell types. Unexpectedly, our data revealed that γ-H2AX induction peaks at 24–48 hours after irradiation in CSCs, providing evidence for delayed DNA repair in CSCs. This delay in DNA repair, combined with an increased period of DNA damage, may provide a window of opportunity for CSCs to accumulate DNA damage, which eventually results in genomic instability. NHEJ occurs predominantly in G1 and G2 during the cell cycle (21). Likewise, the robust activation of DNA-PKcs during the later phase, likely facilitated by Rad50-dependent G2 arrest in cell cycle, induces NHEJ DNA repair and allows cells to reenter the cell cycle and to proliferate. Subsequently, their genomic instability induces oncogenic transformation and promotes cell division in viable CSCs. In addition, DNA-PK–independent modes of NHEJ may exist at the early phase, considering that cancer cells also repair their damaged DNA via alternative NHEJ. These findings identify a time-dependent mechanism that controls radioresistance in CSCs.

Our findings suggest that CSCs selectively utilize DNA-PK to repair their damaged DNA, likely due to the constitutively high expression of DNA-PKcs and relatively low expression of other DNA repair enzymes, including ATM and ATR, as revealed by our comparative RNA-seq analysis. Notably, a recent report shows that skin bulge stem cells exhibit high DNA-PK activity relative to matched non–stem cells (13). This finding is consistent with our results showing stemness-associated DNA-PK expression. Specifically, DNA-PKcs is preferentially expressed in CSCs relative to non-CSCs, suggesting that CSCs may utilize a different DNA repair mechanism in response to therapy-induced DNA damage.

Furthermore, our study reveals a previously unidentified regulatory system capable of controlling DNA-PK activity, in which ROS regulates DNA-PK activity by modulating DNA-PKcs’ interaction with
Figure 6. DNA-PK is critical for genomic instability and radioresistance in CSCs in vivo. Human INS285 CSCs that stably express luciferase and shRNAs targeting control GFP, ATM, or DNA-PK were injected into the brains of nude mice. Using guided micro-CT, mice were locally irradiated with stereotactic x-ray radiation (3 Gy, single dose). (A) Experimental procedure. (B) Animal survival was monitored for 90 days after injection (n = 7–9 mice). P values were determined by log-rank (Mantel-Cox) tests. MS, median survival. (C) Tumor growth was analyzed by bioluminescence. Representative images and quantitative analysis of integrated luminescence in tumors at day 41 (mean ± SEM). P values were determined by t tests. (D) Tumor sections were stained with H&E. Representative images are shown (n = 4–5 mice). Scale bar: 100 μm. (E) Tumor sections were stained by TUNEL. Representative images are shown, and TUNEL+ cells were counted (mean ± SEM, n = 3 mice). Scale bar: 100 μm. (F) Single-cell suspensions derived from tumors were stained with propidium iodide and subjected to aneuploid analysis by flow cytometry. Representative sorting and quantified data (mean ± SEM, n = 4–9 mice) are shown. P values were determined by t tests.
Figure 7. Combined radiotherapy with DNA-PK inhibition eradicates CSCs and improves mouse survival. Primary GBM in Ntv-a;Ink4a-/-;Ptenfl/fl;LSL-Luc donor mice is induced by RCAS-mediated somatic gene transfer. Recipient mice were wild-type B6 mice. Mice were treated with 10 mg/kg NU7441 (iDNA-PK) or KU60019 (iATM) for 8 days and simultaneously irradiated with x-ray (2.5-Gy doses, 4 times). (A) Experimental procedure. (B) Animal survival was monitored for 65 days after injection (n = 10–11 mice). P values were determined by log-rank (Mantel-Cox) tests. MS, median survival. (C) Tumor growth was analyzed by bioluminescence. Representative images and quantitative analysis of integrated luminescence in tumors at day 24 (mean ± SEM). P values were determined by t tests. (D and E) Tumor sections were probed with anti-CD133 antibody and counterstained with hematoxylin. (D) Representative images. Scale bar: 100 mm. (E) Quantitative results (mean ± SD, n = 5 mice). (F) Tumor sections were stained with H&E. Representative images are shown (n = 4–5 mice). Scale bar: 100 μm.
Ku70/80, a key process that induces DNA-PKcs autophosphorylation and activation (22–24). Radiation induces an initial increase in ROS generation, likely due to early direct radiation effects (water radiolysis and OH production) and later indirect mitochondrial dysfunction, followed by a gradual decrease in ROS generation that is likely induced by highly expressed free radical scavenging systems, e.g., glutathione (GSH) biosynthesis, in CSCs (17). These ROS dynamics temporally regulate DNA-PKcs activity, along with the preferential expression of DNA-PKcs and the selective requirement of DNA-PKcs for DNA repair, which serve as dual mechanisms that lead to the delayed, robust activation of DNA-PKcs and NHEJ in CSCs during the later time phase after irradiation.

We report a unique mechanism by which CSCs develop increased malignancy and treatment resistance achieved through enhanced genomic instability. Specifically, the accumulation of DNA damage combined with temporally regulated NHEJ repair could result in a high number of genetic mutations in CSCs, which leads to genomic instability and fuels oncogenic transformation. These findings provide insights into the clinical observation of enhanced malignancy in relapsed tumors that likely are derived from treatment-transformed CSCs. Likewise, genomic instability is a common feature observed during the later stages of primary tumor development or in metastasized tumors at distant sites (25, 26), both of which are highly associated with CSCs (27, 28). In addition, we also expect that genotoxic chemotherapy, e.g., with temozolomide and doxorubicin that damage DNA, may have similar effects on genomic instability in CSCs as radiotherapy. Our data established requisite in vitro and in vivo roles for DNA-PK in maintaining genomic instability in CSCs. In contrast, previous studies show that DNA-PKcs–knockout mice exhibit increased spontaneous and radiation-induced genomic instability in fibroblasts (29), suggesting that this stemness-associated mechanism may strictly depend on the preferential expression of DNA-PKcs over ATM and ATR, the temporally regulated activity of DNA-PKcs, and/or the altered global expression profile of DNA repair-associated genes in CSCs.

Pharmacological inhibition of DNA damage response enzymes, including DNA-PK, ATM, and ATR, has emerged as a crucial strategy for sensitizing tumor cells to radiotherapy and chemotherapy over last two decades (30–32). Recent preclinical studies using these inhibitors show promising results; however, their effects on the sensitization appear marginal to moderate (33–36), possibly due to redundant functions among these kinases and other compensatory mechanisms (30, 31, 37). Previous work also suggests a role of DNA-PK for therapeutic resistance in cancer stem cells by regulating autophagy, expression of multidrug resistance genes, and DNA repair (14, 15, 38). Our results reveal a spatial regulation mechanism and provide evidence that DNA-PK is selectively required for the DNA damage response in glioma CSCs. In this study, we show that DNA-PK inhibition by NU7441, a potent and selective DNA-PK inhibitor (39), eliminates the CSC population and improves the survival of mice bearing gliomas. This result could be subjected to further improvement, considering the limited aqueous solubility and in vivo rapid clearance of NU7441 (31). Interestingly, mice lacking DNA-PKcs develop normally, but humans with null mutations are likely not viable (40). The unique requirement for DNA-PKcs in human cells may be a clinical barrier to developing DNA-PK as a therapeutic target. Thus, development of new and improved pharmacological or genetic approaches that efficiently and sustainably inhibit DNA-PK activity will contribute to CSC-targeted anticancer treatments, which, when combined with additional cytotoxic and targeted therapies, may achieve maximal therapeutic efficacy in cancer intervention.

In summary, our study reveals a time-dependent, DNA-PK–mediated mechanism controlling treatment resistance in glioma CSCs mediated through genomic instability. Furthermore, genetic ablation and pharmacological inhibition of DNA-PK abrogate CSC growth, inhibit glioma progression, and sensitize tumors to radiotherapy in vivo. Thus, targeting DNA-PK may provide an unprecedented opportunity to eliminate CSCs, overcome treatment resistance, and block cancer relapse.
**Methods**

**Cell culture.** Human patient-derived IN528, T3565, T3961, and T4121 glioma CSCs were harvested, characterized, and provided by Jeremy Rich (Cleveland Clinic, Cleveland, Ohio, USA) (9, 41, 42). The stemness of these cells was previously validated by stem cell marker expression (CD133, OLG2, and SOX2), functional assays of self-renewal (serial tumorsphere passage), and in vivo tumor formation assays (41, 43). The matched non-CSCs were generated by brief treatment with medium containing 10% FBS for 24 hours and then were put back into stem cell medium as described previously (9, 44, 45). As an additional control, human GBM patient-derived IN528 cells were incubated with biotinylated anti-CD133 antibody (Miltenyi Biotec, 130090664), and CD133+ and CD133− cells were harvested by magnetic-activated cell sorting with streptavidin-conjugated microbeads (Miltenyi Biotec, 130048101). CSCs were cultured in serum-free Neurobasal-A medium (Gibco), supplemented with B-27 Supplement Minus Vitamin A (Gibco), GlutaMax (Gibco), sodium pyruvate (Gibco), fibroblastic growth factor (5 ng/ml, R&D Systems), and epidermal growth factor (20 ng/ml, R&D Systems). Culture medium was changed every 2 days. Cells were maintained and limited to a low number of passages (less than 5).

**Cell irradiation.** Cells were treated by irradiation by x-ray with a dose rate of 2.8 Gy/min at room temperature using a X-Rad 320x cabinet system (Precision X-Ray). Cells were pretreated with 10 mM ROS scavenger 4-Hydroxy-TEMPO (TEMPOL, MilliporeSigma) and irradiated with single-dose (5-Gy) irradiation.

**Cell viability assay.** Cells were trypsinized, and the single-cell suspensions were loaded into 96-well plates, followed by overnight culture and different treatments. Cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7571) according to the manufacturer’s instructions. Luminescence was detected using a Synergy H4 Hybrid luminescent plate reader (BioTek).

**Clonogenic/sphere-forming assay.** CSCs were trypsinized, and the single-cell suspensions were loaded into 96-well plates. Cells were cultured overnight and subjected to different treatments. After the cells were incubated at 37°C for 14 days, the number of neurospheres in CSCs was counted (46).

**shRNA lentiviral transduction.** The oligonucleotides (sense, 5'-GATCCCGGGCGCTAATCGTACT-GAATTCAAGAGATTCAGTACGATTAGCGCCCTTTTTTGAAA-3', antisense, 3'-GCGGCGGCGGATTAGCATGACTTAAGTTCTCTAAGTCATGCTAATCGCGGGAAAAAACCTTTTCGA-5') that encode small-hairpin RNAs (shRNAs) targeting DNA-PKcs (nucleotides 11637–11655) were synthesized and cloned into the pLV lentivirus expression vector by VectorBuilder (47). Lentiviral expression vectors and packaging vectors (System Biosciences) for 8 hours. The medium was replaced with fresh medium, the cultures were incubated for 48 hours, and the medium supernatants containing lentivirus were collected. CSCs were infected with lentivirus in the presence of 8 μg/ml puromycin (MilliporeSigma). Stable shRNA-expressing cells were selected with 0.5 μg/ml puromycin and were maintained in the culture medium with 0.2 μg/ml puromycin.

**Single-cell gel electrophoresis comet assay.** Cells were subjected to neutral comet assays for detecting DNA double-strand breaks as described previously (48). In brief, after irradiation, cells were washed with PBS, mixed with low-melting agarose (1:10), and loaded into slides. The slides were then immersed in lysis solution (pH 8.0, 30 mM EDTA, 0.5% sodium dodecyl sulfate) overnight at 37°C. After lysis, slides were rinsed 3 times with 90 mM Tris buffer (pH 8.5) containing 90 mM boric acid and 2 mM EDTA and then subjected to horizontal electrophoresis at a rate of 0.6 V/cm for 25 minutes. DNA was stained with propidium iodide (BD Pharmingen) and imaged with an AxioImager A1 fluorescence microscope (Zeiss) equipped with an AxioCam 506 CCD camera (Zeiss). The cell number with DNA comet assay and the DNA percentage in the comet tail region were measured using NIH ImageJ and OpenComet 1.3 software.

**Deep RNA-seq analysis.** IN528, T3961, and T4121 CSCs and matched non-CSCs were cultured and treated with CSC culture medium for 12 hours. Approximately 2 × 10^6 cells were lysed in 1 ml TRIzol (Thermo Fisher), followed by RNA extraction according to the manufacturer’s instructions. The isolated RNA was purified by using an RNeasy Plus Mini Kit (Qiagen). After a quality control step using RNA Nano assay chips with a 2100 bioanalyzer (Agilent), the library was constructed by using a RiboZero protocol with TapeStation (Agilent) and subjected to deep sequencing (125 PE, about 40 megabyte reads for
each sample, Illumina sequencer 2500) in the Next-Generation Sequencing Core at the University of Pennsylvania. Data analysis was performed in the core facility, and gene expression was expressed as FPKM values. About 200 genes encoding all known human proteins associated with DNA damage and repair were classified (http://sciencepark.mdanderson.org/labs/wood/dna_repair_genes.html) and matched with the FPKM expression profile (49–51). RNA-seq data have been deposited in NCBI’s Gene Expression Omnibus under the accession GSE108322.

**ROS assay.** Cells were trypsinized, seeded into white 96-well plates, and cultured overnight, followed by x-ray irradiation. ROS (H2O2) levels were determined using the ROS-GLO H2O2 assay (Promega, G8820) according to the manufacturer’s instructions. Luminescence was measured using a Synergy H4 Hybrid luminescence plate reader (BioTek). Total ROS levels were measured using a Total Reactive Oxygen Species Assay Kit (eBioscience, 88593174). Cells were analyzed using an Accuri C6 flow cytometer (BD Biosciences) with FlowJo software.

**Immunoblot analyses.** Cells were lysed in cell lysis buffer (Cell Signaling, 9803) containing a complete protease inhibitor cocktail (1:1,000, Roche) and Halt phosphatase inhibitor cocktail (1:100, Thermo Fisher). 20 μg total protein was resolved by 4%–15% SDS-PAGE (Bio-Rad) and transferred to PVDF membranes. Membranes were blocked with 5% BSA and incubated with anti-phospho-H2AX-Ser139 (1:2,000, Cell Signaling, 9713), anti–phospho-DNA-PKcs-Ser2056 (1:1,000; Abcam, ab18192), anti-DNA-PKcs antibody (1:1,000; Cell Signaling, 12311), anti–phospho-ATM-Ser1981 (1:1,000, Abcam, ab81292), anti-ATM (1:1,000; Cell Signaling, 2873), anti–phospho-ATR-Ser428 (1:1,000, Cell Signaling, 2853), anti-ATR (1:1,000, Cell Signaling, 13934), anti-PCNA (1:2,000, Cell Signaling, 2586), anti-Rad50 (1:1,000, Cell Signaling, 3427), and anti-GAPDH (1:5,000, Cell Signaling, 2118) antibodies, followed by incubation with a secondary antibody conjugated to horseradish peroxidase (1:2,000; Bio-Rad). Signals were visualized using ECL Prime Western Blotting Detection reagent (Amersham).

**Commmunoprecipitation analysis.** IN528 CSCs were pretreated with 10 mM ROS scavenger 4-Hydroxy-TEMPO (TEMPOL, MilliporeSigma) and irradiated with 5-Gy x-ray. At 4 hours after irradiation, the cells were lysed in coommunoprecipitation buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin). After centrifugation at 15,000 g for 15 minutes, 0.5 μg anti-Ku80 antibody (Thermo Fisher, MA5-12933), anti–DNA-PKcs antibody (Santa Cruz Biotechnology, sc9051), or control IgG (Santa Cruz Biotechnology, sc2027 and sc2025) was added to the supernatants (200 μg total protein), followed by an overnight incubation at 4°C. Protein A/G–conjugated agarose beads (Santa Cruz Biotechnology, sc100) were added to each sample and incubated at 4°C for 2 hours, followed by centrifugation at 1,000 g for 10 minutes. The pellets were washed 4 times with PBS buffer and subjected to immunoblot analysis.

**DNA aneuploidy and cell cycle assay.** DNA aneuploidy was analyzed by flow cytometry as previously described (52, 53). In brief, irradiated cells were washed with PBS and fixed with 70% ethanol. Cells were stained with propidium iodide (BD Pharmingen) in the presence of DNase-free RNase A (0.2 mg/ml, Thermo Fisher). Cells were analyzed using an Accuri C6 flow cytometer (BD Biosciences), and the data were analyzed using FlowJo software.

**In vitro NHEJ assay.** Plasmid-based assays for DNA end joining were performed as described previously (54). Briefly, nuclear proteins were harvested from irradiated IN528 cells by using a Nuclear Extraction Kit (Signosis). 10 μg extracted nuclear protein was incubated with 100 ng BamH1-linearized pEGFP-C1-FLAG plasmid (4,766 bp, Addgene, 46956) in 20 μl reaction buffer (20 mM HEPES, pH 7.5, 80 mM KCl, 10 mM MgCl2, 1 mM ATP, 1 mM DTT) for 1 hour at 25°C. The reactions were terminated by the addition of stop solution (1 μl of 10 mg/ml proteinase K, 2 μl of 0.5 M EDTA, pH 7.5, and 2 μl of 0.5% SDS) and incubated for 30 minutes at 37°C. The DNAs were resolved by agarose gel electrophoresis, followed by ethidium bromide staining. Band intensity of multimers was analyzed by using the NIH ImageJ program. In addition, the nuclear protein was immunoblotted with an anti-PCNA antibody (1:2,000, Cell Signaling, 2586).

**Micronucleus analysis.** The cytokinesis-block micronucleus cytome assay was performed as described previously (55). Briefly, irradiated cells were treated with 4 μg/ml cytochalasin B (MilliporeSigma). The cells were fixed with methanol/acetic acid (3:1, v/v) and stained with DAPI. Scoring of micronuclei was limited to binucleated cells with preserved cytoplasm. The results are expressed as the numbers of the cells with micronuclei per 1,000 binucleated cells.

**Mice.** Six- to eight-week-old, half male and half female, nude mice and wild-type black B6 mice were used (Jackson Laboratory).
RESEARCH ARTICLE

Xenograft glioma model. IN528 CSCs were transduced with lentivirus to express firefly luciferase and an shRNA targeting DNA-PK or ATM, followed by puromycin selection. 2 × 10⁴ cells in a total volume of 2 μl were orthotopically injected into nude mice by using a stereotaxic injection system (Stoelting). Mice were administrated with a focused radiation therapy with a single dose of 3-Gy x-ray, guided by micro-CT in a small animal radiation research platform. Tumor growth was monitored by whole-body bioluminescence using an IVIS 200 Spectrum Imaging System after retro-orbital injection of luciferin (150 mg/kg, GoldBio). Mice were euthanized when they exhibited severe GBM symptoms, including dome head, hemiparesis, or more than 20% of body weight loss. After irradiation, survival was monitored for 90 days.

Genetic glioma model. GBM was induced by RCAS-PDGF/Cre–mediated somatic gene transfer in Ntv-a; Ink4a-Arf⁻/⁻;Pten⁻/⁻;LSL-luc mice as described previously (56–59). Tumors in the donor mice were excised and subjected to mechanical dissociation using a gentleMACS Dissociator (Miltenyi Biotec) and enzymatic digestion with collagenase II (Invitrogen) and dispase (Invitrogen) to obtain single-cell suspensions. Wild-type B6 mice were orthotopically, stereotactically injected with 2 × 10⁵ GBM tumor cells. Tumor growth was monitored by whole-body bioluminescence using an IVIS 200 Spectrum Imaging System after retro-orbital injection of luciferin (150 mg/kg, GoldBio). At 11 days after injection, the mice were treated peritoneally with 10 mg/kg NU7441 (an inhibitor of DNA-PK, SelleckChem) or KU60019 (an inhibitor of ATM, SelleckChem) or control DMSO twice daily for 8 days. The mice were also administrated by focused radiotherapy with a single dose of 2.5 Gy every other day for 4 times using an X-Rad 320ix cabinet system (Precision X-Ray). Mice were euthanized when they exhibited severe GBM symptoms, including dome head, hemiparesis, or more than 20% of body weight loss. After treatment, survival was monitored for 65 days.

Histology and immunohistochemistry. Paraffin sections of mouse tumors were deparaffinized, rehydrated, and subjected to antigen retrieval in Target Retrieve Solution (Dako) at 95°C for 20 minutes. Tissue sections were stained with H&E. Tissues were imaged with an AxioLab microscope (Zeiss) equipped with an AxioCam HRC CCD camera (Zeiss). For immunohistochemistry, paraffin sections were deparaffinized and rehydrated, subjected to antigen retrieval in Target Retrieve Solution at 95°C for 20 minutes, and blocked with 5% horse serum for 1 hour at room temperature. Sections were incubated with anti-CD133 (1:100, Biolegend, 141202) antibody overnight at 4°C. Sections were incubated with biotinylated goat anti-rat IgG (1:200, Vector Laboratories, BA9401), followed by staining with a VECTASTAIN ABC-HRP Kit (Vector Laboratories, PK7200) according to the manufacturer’s instructions.

TUNEL staining. Paraffin sections of mouse tumors were deparaffinized and rehydrated and subjected to in situ apoptosis detection using the Click-iT Plus TUNEL Assay (Life Technology, C10618). Images were acquired with an AxioImager A1 fluorescence microscope (Zeiss) equipped with an AxioCam 506 CCD camera (Zeiss).

Statistics. Student’s t (unpaired 2-tailed analysis) and log-rank tests (Mantel-Cox analysis) were used for statistical analyses between groups using Prism software, and P values less than 0.05 were considered statistically significant.

Study approval. All experiments with mice were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and with the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). All animals were housed in the Association for the Assessment and Accreditation of Laboratory Animal Care–accredited animal facility of the University of Pennsylvania.

Author contributions
YW designed, performed, and analyzed experiments and produced figures. HX prepared RNA and performed the RNA-seq analysis. TL contributed to animal studies. MH and PPB contributed to immunofluorescence analyses. CL and LZ contributed to flow cytometry and RNA-seq analysis. GDK, YG, AM, and CK provided suggestions for experimental design. YF designed and supervised experiments and wrote the manuscript. All authors commented on the manuscript.

Acknowledgments
We are grateful to Jeremy Rich and Eric Holland for providing glioma CSCs and the RCAS-PDGF GBM model, respectively; to Shipa Rao for bioinformatical analyses of RNA-seq data; and to Eric Brown for helpful discussions. This work was supported in part by NIH grants R00HL103792 and R01NS094533 (to YF) and R01CA190415 (to LZ).
Address correspondence to: Yi Fan, Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, SCTR 8-132, Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.9291; Email: fanyi@uphs.upenn.edu.